PriceTargets.com logo

Myomo - MYO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.85
  • Forecasted Upside: 533.69 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.87 As of 08/18/2022 01:00 AM ET
▲ +0.15 (8.72%)

This chart shows the closing price for MYO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Myomo Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MYO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MYO

Analyst Price Target is $11.85
▲ +533.69% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Myomo in the last 3 months. The average price target is $11.85, with a high forecast of $17.00 and a low forecast of $6.70. The average price target represents a 533.69% upside from the last price of $1.87.

This chart shows the closing price for MYO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Myomo. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/26/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/24/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/8/2022Alliance Global PartnersLower TargetBuy$10.00 ➝ $6.70
5/12/2022Alliance Global PartnersLower Target$19.00 ➝ $10.00
3/22/2022Colliers SecuritiesReiterated RatingBuy
3/10/2022Alliance Global PartnersLower Target$34.00 ➝ $19.00
11/15/2021Roth CapitalReiterated RatingBuy
11/11/2021Colliers SecuritiesReiterated RatingBuy$17.00
11/11/2021Alliance Global PartnersReiterated RatingBuy$36.50 ➝ $34.00
8/10/2021Colliers SecuritiesReiterated RatingBuy$17.00
6/10/2021Alliance Global PartnersInitiated CoverageBuy
3/8/2021Colliers SecuritiesReiterated RatingBuy$16.00
1/11/2021SidotiBoost Target$11.00 ➝ $14.00
11/11/2020Roth CapitalUpgradeNeutral ➝ Buy$7.00
9/16/2020Colliers SecuritiesBoost TargetBuy$7.00 ➝ $8.00
5/27/2020Dougherty & CoReiterated RatingBuy
5/27/2020Dougherty & CoInitiated CoverageBuy$8.50
3/23/2020Ascendiant Capital MarketsLower TargetPositive ➝ Buy$45.00 ➝ $15.00
11/14/2019Roth CapitalDowngradeBuy ➝ Neutral
11/13/2019Roth CapitalDowngradeBuy ➝ Neutral
8/30/2019Roth CapitalSet TargetBuy$2.00
8/30/2019Roth CapitalLower TargetBuy$2.75 ➝ $1.75
7/30/2019Ascendiant Capital MarketsInitiated CoverageBuy$2.00
2/5/2019Roth CapitalReiterated RatingBuy
11/8/2018Roth CapitalReiterated RatingBuy
8/14/2018HC WainwrightSet TargetBuy$12.00
5/10/2018Roth CapitalSet TargetBuy$9.00 ➝ $7.00
5/10/2018HC WainwrightSet TargetBuy$12.00
3/9/2018Roth CapitalInitiated CoverageBuy$9.00
3/8/2018HC WainwrightSet TargetBuy$12.00
10/2/2017HC WainwrightReiterated RatingBuy
10/2/2017HC WainwrightInitiated CoverageBuy ➝ Buy$12.00
(Data available from 8/19/2017 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/21/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/20/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/22/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/21/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2022
  • 4 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2022

Current Sentiment

  • 0 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Myomo logo
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $1.87
Low: $1.73
High: $1.90

50 Day Range

MA: N/A

52 Week Range

Now: $1.87
Low: $1.60
High: $14.35

Volume

49,844 shs

Average Volume

78,862 shs

Market Capitalization

$13.09 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Myomo?

The following Wall Street sell-side analysts have issued research reports on Myomo in the last twelve months: Alliance Global Partners, Colliers Securities, and Roth Capital.
View the latest analyst ratings for MYO.

What is the current price target for Myomo?

2 Wall Street analysts have set twelve-month price targets for Myomo in the last year. Their average twelve-month price target is $11.85, suggesting a possible upside of 533.7%. Colliers Securities has the highest price target set, predicting MYO will reach $17.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $6.70 for Myomo in the next year.
View the latest price targets for MYO.

What is the current consensus analyst rating for Myomo?

Myomo currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MYO will outperform the market and that investors should add to their positions of Myomo.
View the latest ratings for MYO.

What other companies compete with Myomo?

Other companies that are similar to Myomo include Bone Biologics, NanoVibronix, Allied Healthcare Products, Ortho Regenerative Technologies and Bionik Laboratories. Learn More about companies similar to Myomo.

How do I contact Myomo's investor relations team?

Myomo's physical mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The company's listed phone number is (617) 996-9058 and its investor relations email address is [email protected] The official website for Myomo is myomo.com. Learn More about contacing Myomo investor relations.